A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells' ability to survive and grow.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback